1887

Abstract

The partial success of the RV144 trial underscores the importance of envelope-specific antibody responses for an effective HIV-1 vaccine. Oligomeric HIV-1 envelope proteins delivered with a potent adjuvant are expected to elicit strong antibody responses with broad neutralization specificity. To test this hypothesis, two SIV envelope proteins were formulated with delta inulin-based adjuvant (Advax) and used to immunize nonhuman primates. Oligomeric gp140–gp145 from SIVmac251 and SIVsmE660 was purified to homogeneity. Oligomers showed high-affinity interaction with CD4 and were highly immunogenic in rabbits, inducing Tier 2 SIV-neutralizing antibodies. The immunogenicity of an oligomeric Env DNA prime and protein boost together with Advax was evaluated in Chinese rhesus macaques. DNA administration elicited antibodies to both envelopes, and titres were markedly enhanced following homologous protein boosts via intranasal and intramuscular routes. Strong antibody responses were detected against the V1 and V2 domains of gp120. During peak immune responses, a low to moderate level of neutralizing activity was detected against Tier 1A/1B SIV isolates, with a moderate level noted against a Tier 2 isolate. Increased serum antibody affinity to SIVmac251 gp140 and generation of Env-specific memory B cells were observed in the immunized macaques. Animals were subjected to low-dose intravaginal challenge with SIVmac251 one week after the last protein boost. One out of three immunized animals was protected from infection. Although performed with a small number of macaques, this study demonstrates the utility of oligomeric envelopes formulated with Advax in eliciting broad antibody responses with the potential to provide protection against SIV transmission.

Keyword(s): Advax , BLI , envelope , HIV , SIV and vaccine
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000863
2017-07-31
2019-09-18
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/8/2143.html?itemId=/content/journal/jgv/10.1099/jgv.0.000863&mimeType=html&fmt=ahah

References

  1. HIV/AIDS, J. U. N. P. o Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. According to the UNAIDS’estimate the Number of New Infections in the Region Increased From 21, 22,000-047,000 Geneva: UNAIDS; 2015
    [Google Scholar]
  2. HIV/AIDS, J. U. N. P. o Global AIDS Update Geneva: UNAIDS: 2016
    [Google Scholar]
  3. Letvin NL, Barouch DH, Montefiori DC. Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol 2002;20:73–99 [CrossRef][PubMed]
    [Google Scholar]
  4. Nabel GJ. Challenges and opportunities for development of an AIDS vaccine. Nature 2001;410:1002–1007 [CrossRef][PubMed]
    [Google Scholar]
  5. Nabel GJ. HIV vaccine strategies. Vaccine 2002;20:1945–1947 [CrossRef][PubMed]
    [Google Scholar]
  6. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209–2220 [CrossRef][PubMed]
    [Google Scholar]
  7. de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S et al. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 2012;188:5166–5176 [CrossRef][PubMed]
    [Google Scholar]
  8. Haynes BF, Gilbert PB, Mcelrath MJ, Zolla-Pazner S, Tomaras GD et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366:1275–1286 [CrossRef][PubMed]
    [Google Scholar]
  9. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 2012;206:431–441 [CrossRef][PubMed]
    [Google Scholar]
  10. Ko SY, Pegu A, Rudicell RS, Yang ZY, Joyce MG et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 2014;514:642–645 [CrossRef][PubMed]
    [Google Scholar]
  11. Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA 2012;109:18921–18925 [CrossRef][PubMed]
    [Google Scholar]
  12. Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med 2014;6:243ra88 [CrossRef][PubMed]
    [Google Scholar]
  13. Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol 2014;88:12669–12682 [CrossRef][PubMed]
    [Google Scholar]
  14. Shingai M, Donau OK, Plishka RJ, Buckler-White A, Mascola JR et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med 2014;211:2061–2074 [CrossRef][PubMed]
    [Google Scholar]
  15. Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP et al. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 2007;360:329–340 [CrossRef][PubMed]
    [Google Scholar]
  16. Grundner C, Li Y, Louder M, Mascola J, Yang X et al. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology 2005;331:33–46 [CrossRef][PubMed]
    [Google Scholar]
  17. Kim M, Qiao ZS, Montefiori DC, Haynes BF, Reinherz EL et al. Comparison of HIV type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. AIDS Res Hum Retroviruses 2005;21:58–67 [CrossRef][PubMed]
    [Google Scholar]
  18. Kovacs JM, Nkolola JP, Peng H, Cheung A, Perry J et al. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci USA 2012;109:12111–12116 [CrossRef][PubMed]
    [Google Scholar]
  19. Nkolola JP, Peng H, Settembre EC, Freeman M, Grandpre LE et al. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J Virol 2010;84:3270–3279 [CrossRef][PubMed]
    [Google Scholar]
  20. Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 2013;9:e1003618 [CrossRef][PubMed]
    [Google Scholar]
  21. Cristillo AD, Wang S, Caskey MS, Unangst T, Hocker L et al. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology 2006;346:151–168 [CrossRef][PubMed]
    [Google Scholar]
  22. Pal R, Kalyanaraman VS, Nair BC, Whitney S, Keen T et al. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 2006;348:341–353 [CrossRef][PubMed]
    [Google Scholar]
  23. Pal R, Wang S, Kalyanaraman VS, Nair BC, Whitney S et al. Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J Med Primatol 2005;34:226–236 [CrossRef][PubMed]
    [Google Scholar]
  24. Wang S, Kennedy JS, West K, Montefiori DC, Coley S et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008;26:3947–3957 [CrossRef][PubMed]
    [Google Scholar]
  25. Li J, Valentin A, Kulkarni V, Rosati M, Beach RK et al. HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine 2013;31:3747–3755 [CrossRef][PubMed]
    [Google Scholar]
  26. Bielefeldt-Ohmann H, Prow NA, Wang W, Tan CS, Coyle M et al. Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals. Vet Res 2014;45:130 [CrossRef][PubMed]
    [Google Scholar]
  27. Cristillo AD, Ferrari MG, Hudacik L, Lewis B, Galmin L et al. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J Gen Virol 2011;92:128–140 [CrossRef][PubMed]
    [Google Scholar]
  28. Honda-Okubo Y, Kolpe A, Li L, Petrovsky N. A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax™) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection. Vaccine 2014;32:4651–4659 [CrossRef][PubMed]
    [Google Scholar]
  29. Larena M, Prow NA, Hall RA, Petrovsky N, Lobigs M. JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibody. J Virol 2013;87:4395–4402 [CrossRef][PubMed]
    [Google Scholar]
  30. Layton RC, Petrovsky N, Gigliotti AP, Pollock Z, Knight J et al. Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. Vaccine 2011;29:6242–6251 [CrossRef][PubMed]
    [Google Scholar]
  31. Rangasamy SP, Menon V, Dhopeshwarkar P, Pal R, Vaniambadi KS et al. Membrane bound Indian clade C HIV-1 envelope antigen induces antibodies to diverse and conserved epitopes upon DNA prime/protein boost in rabbits. Vaccine 2016;34:2444–2452 [CrossRef][PubMed]
    [Google Scholar]
  32. Sneha Priya R, Veena M, Kalisz I, Whitney S, Priyanka D et al. Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate. J Biol Chem 2015;290:9195–9208 [CrossRef][PubMed]
    [Google Scholar]
  33. Bricault CA, Kovacs JM, Nkolola JP, Yusim K, Giorgi EE et al. A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component. J Virol 2015;89:2507–2519 [CrossRef][PubMed]
    [Google Scholar]
  34. Earl PL, Sugiura W, Montefiori DC, Broder CC, Lee SA et al. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol 2001;75:645–653 [CrossRef][PubMed]
    [Google Scholar]
  35. Sharma SK, de Val N, Bale S, Guenaga J, Tran K et al. Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. Cell Rep 2015;11:539–550 [CrossRef][PubMed]
    [Google Scholar]
  36. Yang X, Lee J, Mahony EM, Kwong PD, Wyatt R et al. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 2002;76:4634–4642 [CrossRef][PubMed]
    [Google Scholar]
  37. Liu L, Hao Y, Luo Z, Huang Y, Hu X et al. Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization. Vaccine 2012;30:4135–4143 [CrossRef][PubMed]
    [Google Scholar]
  38. Sundling C, Forsell MN, O'Dell S, Feng Y, Chakrabarti B et al. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J Exp Med 2010;207:2003–2017 [CrossRef][PubMed]
    [Google Scholar]
  39. Wieczorek L, Krebs SJ, Kalyanaraman V, Whitney S, Tovanabutra S et al. Comparable antigenicity and immunogenicity of oligomeric forms of a novel, acute HIV-1 subtype C gp145 envelope for use in preclinical and clinical vaccine research. J Virol 2015;89:7478–7493 [CrossRef][PubMed]
    [Google Scholar]
  40. Mason RD, Welles HC, Adams C, Chakrabarti BK, Gorman J et al. Targeted isolation of antibodies directed against major sites of SIV Env vulnerability. PLoS Pathog 2016;12:e1005537 [CrossRef][PubMed]
    [Google Scholar]
  41. Doores KJ, Burton DR. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 2010;84:10510–10521 [CrossRef][PubMed]
    [Google Scholar]
  42. Kim AS, Leaman DP, Zwick MB. Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization. PLoS Pathog 2014;10:e1004271 [CrossRef][PubMed]
    [Google Scholar]
  43. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326:285–289 [CrossRef][PubMed]
    [Google Scholar]
  44. Petrovsky N, Larena M, Siddharthan V, Prow NA, Hall RA et al. An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody. J Virol 2013;87:10324–10333 [CrossRef][PubMed]
    [Google Scholar]
  45. Li L, Honda-Okubo Y, Li C, Sajkov D, Petrovsky N. Delta inulin adjuvant enhances plasmablast generation, expression of activation-induced cytidine deaminase and B-cell affinity maturation in human subjects receiving seasonal influenza vaccine. PLoS One 2015;10:e0132003 [CrossRef][PubMed]
    [Google Scholar]
  46. Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008;22:339–348 [CrossRef][PubMed]
    [Google Scholar]
  47. Jalah R, Kulkarni V, Patel V, Rosati M, Alicea C et al. DNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in macaques. PLoS One 2014;9:e91550 [CrossRef][PubMed]
    [Google Scholar]
  48. Vargas-Inchaustegui DA, Tuero I, Mohanram V, Musich T, Pegu P et al. Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses. Clin Immunol 2014;153:308–322 [CrossRef][PubMed]
    [Google Scholar]
  49. Valentin A, von Gegerfelt A, Rosati M, Miteloudis G, Alicea C et al. Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit. Vaccine 2010;28:1962–1974 [CrossRef][PubMed]
    [Google Scholar]
  50. von Gegerfelt AS, Rosati M, Alicea C, Valentin A, Roth P et al. Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. J Virol 2007;81:1972–1979 [CrossRef][PubMed]
    [Google Scholar]
  51. Murugappan S, Frijlink HW, Petrovsky N, Hinrichs WL. Enhanced pulmonary immunization with aerosolized inactivated influenza vaccine containing delta inulin adjuvant. Eur J Pharm Sci 2015;66:118–122 [CrossRef][PubMed]
    [Google Scholar]
  52. Rajapaksa AE, Ho JJ, Qi A, Bischof R, Nguyen TH et al. Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization. Respir Res 2014;15:60 [CrossRef][PubMed]
    [Google Scholar]
  53. Guenaga J, de Val N, Tran K, Feng Y, Satchwell K et al. Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties. PLoS Pathog 2015;11:e1004570 [CrossRef][PubMed]
    [Google Scholar]
  54. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013;342:1477–1483 [CrossRef][PubMed]
    [Google Scholar]
  55. Feng Y, Tran K, Bale S, Kumar S, Guenaga J et al. Thermostability of Well-Ordered HIV spikes correlates with the elicitation of autologous tier 2 neutralizing antibodies. PLoS Pathog 2016;12:e1005767 [CrossRef][PubMed]
    [Google Scholar]
  56. Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ et al. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 2015;349:aac4223 [CrossRef]
    [Google Scholar]
  57. Pal R, Venzon D, Letvin NL, Santra S, Montefiori DC et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol 2002;76:292–302 [CrossRef][PubMed]
    [Google Scholar]
  58. Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol 2005;Chapter 12:12.11. 11-12.11. 17 [CrossRef][PubMed]
    [Google Scholar]
  59. Lee EM, Chung HK, Livesay J, Suschak J, Finke L et al. Molecular methods for evaluation of virological status of nonhuman primates challenged with simian immunodeficiency or simian-human immunodeficiency viruses. J Virol Methods 2010;163:287–294 [CrossRef][PubMed]
    [Google Scholar]
  60. Romano JW, Shurtliff RN, Dobratz E, Gibson A, Hickman K et al. Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. J Virol Methods 2000;86:61–70 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000863
Loading
/content/journal/jgv/10.1099/jgv.0.000863
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error